首页 | 本学科首页   官方微博 | 高级检索  
     


Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children
Authors:Riccardo Masetti  Francesca Vendemini  Paola Quarello  Katia Girardi  Arcangelo Prete  Franca Fagioli  Andrea Pession  Franco Locatelli
Abstract:
Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT). While the use of thrombopoietin receptor agonists was retrospectively investigated in adults, data in pediatric posttransplant thrombocytopenia are lacking. We evaluated the safety and efficacy of eltrombopag in nine children with platelet transfusion‐dependent persistent thrombocytopenia after HSCT. Eltrombopag was started at a median of 147 days after allo‐SCT and continued for a median period of 64 days, the starting dose being 50 mg per day. The therapy was well tolerated. After a median time of treatment of 36 days, eight patients (88%) reached sustained platelets count >50 000/μL.
Keywords:eltrombopag  pediatric hematopoietic stem cell transplantation  thrombocytopenia  thrombopoietin receptor agonists
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号